News

APVO436 appears to be safe and effective for the treatment of acute myeloid leukemia or myelodysplastic syndrome.

E777 is a reformulation of a previous FDA approved agent for CTLC that was pulled from the market voluntarily for improvements.

Tegavivint is being tested in combination with osimertinib in an effort to prolong overall survival and deepen response in EGFR+ NSCLC.

ST101 was granted a fast track designation based on preliminary data of an ongoing phase 1/2 trial.

In a phase 3 clinical trial, avasopasem appeared to lower the rate of severe oral mucositis in patients.

The FDA has granted approval to abatacept, the first drug for the prevention of graft versus host disease.

Following an orphan drug designation earlier in 2021, NUV-422 has been granted a fast track designation for the treatment of high-grade gliomas.

All 248 patients with endometrial cancer have been enrolled in the phase 3 SIENDO clinical trial.

Cilta-Cel produced an overall response of 95% in patients with heavily pretreated multiple myeloma.

Rajneesh Nath, MD, discusses the design of the SIERRA trial (NCT02665065), which evaluated 131 I apamistamab (Iomab-B) in elderly patients with relapsed/refractory acute myeloid leukemia.

Full-dose pacritinib beats ruxolitinib in patients with cytopenic myelofibrosis.

Results from the REVEAL study signal link between thrombotic events and white blood cell counts.

Tisagenlecleucel failed to improve event-free survival in the second-line setting of relapsed or refractory aggreesve B-cell non-Hodgkin lymphoma versus standard-of-care.

The considerations investigators must take into account when designing clinical trials include patient population, previous therapies, assessment of the central nervous system, end points, and leptomeningeal disease, according to the new guidelines.

While no significant difference in overall survival benefit between the treatment groups was observed, almost all patients switched from FCR to ibrutinib or another regimen after disease relapse.

The investigational agent glofitamab produced high responder rates in combination with obinutuzumab in multiple relapsed or refractory follicular lymphoma.

The novel non-covalent BTK inhibitor pirtobrutinib has shown encouraging preclinical efficacy in addressing resistance to ibrutinib and venetoclax resistance in mantle cell lymphoma models cell lines.

Retrospective data from tafasitamab plus lenalidomide for the treatment of relapsed or refractory diffuse large B-cell lymphoma correlate with real-world findings.

Based on findings from extended follow-up analysis of the phase 2 ELARA study, tisagenlecleucel is a beneficial treatment for patients with relapsed or refractory follicular lymphoma.

Monsunetuzumab induced deep and durable remission in patients with heavily pretreated follicular lymphoma.

Based on updated findings from the phase 2 SUMMIT trial, a neratinib triplet and neratinib doublet can induce responses in patients with HER2-positive breast cancer.

The combination of obinutuzumab with polatuzumab vedotin, or lenalidomide may be a solution for the toxicity sometimes observed with chimeric antigen receptor T cells in patients with follicular lymphoma.

Darovasertib and crizotinib demonstrated promising efficacy and tolerable safety in patients with metastatic uveal melanoma, according to preliminary results of a phase 1/2 trial announced in a press release from IDEAYA Biosciences.

The Ocomine Dx Target Test is now FDA-approved to help identify eligible patients to be treated with amivantamab.

Adding zanidatamab to chemotherapy may result in positive efficacy and safety outcomes in patients with HER2-positive breast cancer.

The ability to prolong central nervous system progression-free survival in patients with hormone receptor–positive, HER2-positive breast cancer has been demonstrated in an early clinical trial.

BOVen was found to induce MRD and to have a tolerable safety profile.

The application for poziotinib is supported by the phase 2 ZENITH20 trial. The agent showed a promising safety profile and antitumor activity.

Andrea Moreira, MD, a board-certified plastic surgeon specializing in the use of advanced techniques in breast reconstruction, has joined Allegheny Health Network.